Full-Time

Accounting Manager

Posted on 10/31/2025

Colossal

Colossal

201-500 employees

Gene editing for de-extinction of megafauna

No salary listed

Dallas, TX, USA

In Person

On-site in Dallas, TX; up to 10% travel may be required.

Category
Accounting (1)
Requirements
  • Proficient with US Generally Accepted Accounting Principles and financial reporting.
  • High degree of attention to detail and accuracy.
  • Ability to function well in a growth-oriented, nimble environment. Willingness to contribute where support is needed across finance.
  • Ambitious with a desire to continue to learn.
  • Strong analytical skills and experience using data to help make strategic decisions.
  • Ability to communicate clearly so others can understand.
  • Practiced interpersonal skills.
  • Accounts Payable, Invoicing, and Payroll experience are a plus.
  • Experience with NetSuite, QuickBooks, Bill.com preferred.
  • Advanced skills in Excel, including Vlookups and Pivot Tables preferred.
  • A Bachelor's degree is required (preferably in Accounting, Finance, or related field).
  • 4 or more years of accounting experience is required.
  • Previous experience with a Big 4 Accounting firm is a plus.
  • Previous experience in the biotech industry is preferred.
  • Experience in a fast growth scale up or start-up is a plus.
Responsibilities
  • Assist with the month end, quarter end and year end close process including related journal entries, account reconciliations, international consolidation of multiple entities and working papers and ensure compliance with US GAAP.
  • Maintain and reconcile balance sheet general ledger accounts, including, but not limited to, cash and investments, prepaid expenses, fixed assets, accounts payable, and accrued liabilities.
  • Collaborate cross-functionally with R&D and non-finance/accounting teams to ensure timely and accurate financial data.
  • Work closely with the Corporate Controller to assist with the preparation of annual financial statements, cash flows and associated notes.
  • Support the annual audit process and other audit requests.
  • Ensure compliance with internal controls and accounting standards.
  • Continuously analyze current accounting/finance processes and internal controls and present improvement suggestions, as needed. Ensure that internal policies and SOX procedures are adhered to.
  • Ownership of ad-hoc projects and analysis to support business decision making and mitigate risks.
  • Proactively provide observations/recommendations to all levels of management in order to gain efficiencies in the monthly GL Close process. Assist in making necessary changes to gain efficiencies identified.
Desired Qualifications
  • Experience with NetSuite, QuickBooks, Bill.com preferred.
  • Advanced skills in Excel, including Vlookups and Pivot Tables preferred.
  • Previous Big 4 accounting firm experience is a plus.
  • Previous experience in the biotech industry is preferred.
  • Experience in a fast growth scale up or start-up is a plus.

Colossal develops gene editing approaches to revive extinct or endangered species and restore ecological balance. It collects viable DNA samples and edits genes to rebuild traits of lost megafauna, with Woolly Mammoth as a leading project. Its technology translates into practical applications for species recovery and conservation, aiming to kickstart biodiversity and support the biology economy. Distinctive aspects include a focus on de-extinction tied to ecological restoration, leadership from Ben Lamm and George Church, and a strategy that links scientific capability with real-world ecological and economic benefits. The company’s goal is to reawaken lost wilds to help ecosystems recover and allow humanity to coexist with a healthier planet.

Company Size

201-500

Company Stage

Series C

Total Funding

$625M

Headquarters

Austin, Texas

Founded

2021

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquired ViaGen in 2025, birthed dire wolf pups Romulus, Remus, Khaleesi in April 2025.
  • Secured $60M UAE funding for Dubai BioVault preserving 10,000+ species genomes.
  • Spun out Astromech AI at $2B valuation, accelerating genomics with $120M avian funding.

What critics are saying

  • Dodo pipeline fails viability in 24-36 months, eroding confidence post-$120M raise.
  • Viagen scandals trigger FDA scrutiny on gene-edited animals within 12-18 months.
  • UAE BioVault seized amid tensions, locking out assets in 18-24 months.

What makes Colossal unique

  • Colossal pioneers CRISPR for de-extinction of woolly mammoth using elephant iPSCs.
  • First company to reprogram elephant iPSCs with Oct4, Sox2, Klf4 for mammoth traits.
  • Edits dunnart genomes with 300+ changes for thylacine revival, most edited animal cell.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Spending Account/Flexible Spending Account

401(k) Company Match

Paid Parental Leave

Education Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
The Business Journals
Apr 3rd, 2026
Dallas billionaire's second startup reaches $2B valuation with AI predicting diseases

A second startup from Dallas billionaire Ben Lamm has achieved unicorn status with a $2 billion valuation in its latest funding round. Lamm, who also co-founded and leads Colossal Biosciences, has seen his new venture reach the milestone valuation. The company focuses on predicting biology, evolution and diseases before they occur. This marks Lamm's second startup to surpass the $1 billion valuation threshold, following his success with Colossal Biosciences.

GamesBeat
Mar 26th, 2026
Colossal Biosciences spins out AI startup Astromech at $2B valuation

Colossal Biosciences, which is trying to bring back the wooly mammoth with genetics tech, has spun out its AI startup Astromech at a $2 billion valuation.

Dallas Innovates
Feb 3rd, 2026
Dallas-based Colossal gets $60M from UAE, will build modern 'Noah's Ark' in Dubai

Dallas-based Colossal Biosciences has secured $60 million from the United Arab Emirates to build the Colossal BioVault and World Preservation Lab at Dubai's Museum of the Future. The investment is part of Colossal's expanded Series C round, bringing total funding to over $615 million. The facility will house millions of samples representing more than 10,000 species, initially focusing on the 100 most imperiled species not currently preserved elsewhere. Using automated robotics, AI monitoring and cryopreservation technology, the project aims to create a backup system for Earth's biodiversity. The initiative addresses the threat that nearly half of Earth's species could face extinction by 2050. The Dubai facility will eventually form part of a global network of BioVaults. Visitors will observe scientists working in real time on DNA sequencing and cell line preservation.

PR Newswire
Feb 3rd, 2026
UAE partners with Colossal Biosciences in nine-figure deal to establish global species preservation vault

The UAE has partnered with Colossal Biosciences to establish a laboratory and BioVault at Dubai's Museum of the Future, positioning the nation as a global leader in conservation and biodiversity protection. The initiative represents a nine-figure investment, with the UAE contributing to Colossal's recent funding round. The Colossal BioVault will preserve genetic material from over 10,000 species, initially focusing on the 100 most imperiled species not currently banked elsewhere. The facility will use automated robotics, AI monitoring and proprietary cryopreservation technology to store millions of samples. The project addresses the biodiversity crisis, with nearly half of Earth's species potentially facing extinction by 2050. The BioVault will serve as a research hub, generating genomic data and reference genomes whilst operating as a live laboratory where visitors can witness preservation work in real time.

Business Wire
Nov 5th, 2025
Colossal Biosciences Acquires Viagen, the Leader in Animal Cloning

Colossal Biosciences, the world’s de-extinction company, today announced its acquisition of Viagen Pets and Equine, the global leader and expert in animal cl...

INACTIVE